Published in Bone Marrow Transplant on December 17, 2007
Adult acute lymphoblastic leukemia: concepts and strategies. Cancer (2010) 1.78
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.56
Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2009) 1.46
Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol (2009) 1.16
Intensive care outcomes in bone marrow transplant recipients: a population-based cohort analysis. Crit Care (2008) 1.04
Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation. Oncotarget (2016) 0.91
Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioning. Exp Hematol Oncol (2015) 0.76
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood (2005) 3.63
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood (2003) 3.30
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood (2002) 2.56
Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol (2004) 2.11
Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica (2005) 1.93
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer (1999) 1.90
Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant (2002) 1.89
Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica (2003) 1.82
Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). Biol Blood Marrow Transplant (2005) 1.75
Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol (2004) 1.68
Adult acute lymphoblastic leukemia. Mayo Clin Proc (2005) 1.03
Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program (2001) 1.00
Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options. Bone Marrow Transplant (2006) 0.99
Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol (2006) 0.98
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am (2000) 0.97
GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica (2004) 0.93
Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol. Br J Haematol (1997) 0.92
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant (2002) 0.88
Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. Ann Intern Med (1995) 0.88
Validation of DNA-based HLA-A and HLA-B testing of volunteers for a bone marrow registry through parallel testing with serology. Tissue Antigens (2001) 0.87
Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood (1991) 0.87
Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol (1994) 0.87
Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia (2006) 0.85
The National Marrow Donor Program: improving access to hematopoietic stem cell transplantation. Clin Transpl (1999) 0.85
Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood (1997) 0.83
Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplant (1998) 0.83
Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood (1994) 0.82
Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant (1997) 0.81
The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood (2002) 0.81
Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome. Br J Haematol (1994) 0.81
Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant (2005) 0.80
Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. J Clin Oncol (1990) 0.80
Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission. Leuk Res (1998) 0.78
Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia (1989) 0.78
Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant (1997) 0.77
Trends in transplantation of hematopoietic stem cells from unrelated donors. Curr Opin Hematol (2001) 0.77
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98
Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy (2005) 5.92
Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest (2000) 5.88
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med (2001) 5.14
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med (1997) 4.98
All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 4.52
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med (2000) 4.50
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia (2007) 3.95
Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol (2000) 3.94
Independent origins and horizontal transfer of bacterial symbionts of aphids. Mol Ecol (2001) 3.84
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center. Ann Intern Med (1973) 3.81
Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med (1994) 3.26
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother (1993) 3.25
Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant (2002) 3.24
Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant (2007) 3.18
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol (1998) 3.06
Optimizing the biolistic process for different biological applications. Methods Enzymol (1993) 2.98
Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med (1982) 2.97
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med (1993) 2.90
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis (1998) 2.78
Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med (1972) 2.75
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood (2000) 2.65
Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med (1999) 2.60
Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med (1977) 2.52
Electric field-mediated DNA transfer: transient and stable gene expression in human and mouse lymphoid cells. Mol Cell Biol (1986) 2.51
Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant (2007) 2.47
Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol (1989) 2.36
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol (1995) 2.33
Isolated chloroma: the effect of early antileukemic therapy. Ann Intern Med (1995) 2.29
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia (2013) 2.25
T-cell depletion of HLA-identical transplants in leukemia. Blood (1991) 2.25
Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood (2001) 2.20
Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med (1990) 2.20
The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine (Baltimore) (1993) 2.18
Physiology of vasopressin relevant to management of septic shock. Chest (2001) 2.17
Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood (1993) 2.12
Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and nonseptic humans. JAMA (1993) 2.11
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 2.10
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
Decreasing frequency but worsening mortality of acute respiratory failure secondary to AIDS-related Pneumocystis carinii pneumonia. Chest (1994) 2.10
Problems of early infancy, formula changes, and mothers' beliefs about their infants. J Pediatr (1985) 2.09
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone Marrow Transplant (2002) 2.06
Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus (2001) 2.04
Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant (2013) 2.04
Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant (2007) 2.03
A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest (1997) 2.00
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2001) 2.00
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 1.98
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med (2001) 1.97
A simplified method of CD34+ cell determination for peripheral blood progenitor cell transplantation and correlation with clinical engraftment. Exp Hematol (1998) 1.96
Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia (2006) 1.95
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol (2000) 1.92
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol (2005) 1.88
Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol (2000) 1.82
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant (2011) 1.82
Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant (2001) 1.82
Do facial expressions signal specific emotions? Judging emotion from the face in context. J Pers Soc Psychol (1996) 1.81
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst (2000) 1.81
Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG) Ann Intern Med (1994) 1.81
Cerebellar abscess. A review of 47 cases. J Neurol Neurosurg Psychiatry (1975) 1.79
Observation scales to identify serious illness in febrile children. Pediatrics (1982) 1.78
Purification and properties of a nuclear exoribonuclease from Ehrlich ascites tumor cells. Proc Natl Acad Sci U S A (1967) 1.77
Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med (1974) 1.77
Value of the C-reactive protein test in the differentiation of bacterial and viral pneumonia. J Pediatr (1978) 1.76
Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol (2001) 1.76
Malignant neoplasms following bone marrow transplantation. Blood (1996) 1.76
Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood (1994) 1.75
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1997) 1.75
Phase I clinical and pharmacokinetic study of taxol. Cancer Res (1987) 1.74
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood (2001) 1.74
Mothers' perceptions of problems of feeding and crying behaviors. A prospective study. Am J Dis Child (1985) 1.74
Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med (1988) 1.73
High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood (1998) 1.72
Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med (1994) 1.71
Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol (1995) 1.71
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia (2006) 1.71
New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant (2008) 1.70
Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA (1993) 1.70
Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant (2001) 1.67
Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant (2006) 1.67